Oragenics, Inc. Preparing for Phase II Clinical Trials To Treat Concussion

UF Innovate | Accelerate Sid Martin graduate company Oragenics announced the approval of Phase II clinical trials for their novel drug-device aimed at treating mild Traumatic Brain Injury, or concussion. The drug is delivered to patients as a powder through the nose, and Phase I studies showed the drug to be safe and well-tolerated. In animal testing, the drug improved behavioral outcomes including memory and motor performance in subjects with brain injuries.

It’s estimated there are 69 million concussions reported annually, and 20% of concussed patients will suffer from post concussion syndrome, which is linked to long term disability.